Landscapes / Glandular and Epithelial Neoplasms

Mesothelial Neoplasms

46 drugs in active Mesothelial Neoplasms trials · Updated 18 Nov 2026

Furthest along
2 in Phase 3
22 in Phase 2
Next Phase 3 result
1 May 2028
Drugs
46
In active trials, any stage
Trials
45 active
1 sub-disease included

Drugs46

DrugHow it worksCompanyStageNext dateDetails
—
Phase 3 1 May 2028Phase 3 trial completes
Multi-specific immunoglobulin
AstraZeneca · Public AZN
Phase 3 16 Nov 2028Phase 3 trial completes
—
Phase 1/2 14 Mar 2027Phase 1/2 trial completes
PD-1 antibody
Merck & Co. · Public MRK
Phase 2 4 May 2027Phase 2 trial completes
—
Phase 1/2 Jun 2027Phase 1/2 trial completes
—
Phase 1/2 31 Aug 2027Phase 1/2 trial completes
—
Phase 1/2 31 Dec 2027Phase 1/2 trial completes
—
Phase 1/2 Dec 2027Phase 1/2 trial completes
—
Phase 1/2 31 Jan 2028Phase 1/2 trial completes
—
Phase 1/2 Jan 2028Phase 1/2 trial completes

See all 46 drugs

Sign in free to see the whole list. No card, no password.

Sign in free

Included1

Sub-diseaseDrugsActive trialsTrials
Mesothelioma
1 sub-disease
4645

About

Summary
46 drugs are in active Mesothelial Neoplasms trials: 2 in Phase 3, 44 earlier. The next Phase 3 result expected is VT3989’s, 1 May 2028. Updated 18 Nov 2026.
Registry term
Neoplasms, Mesothelial
Counts
Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
Sources
ClinicalTrials.gov updated 18 Nov 2026